TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00757289

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP Injection
Description: PRP Injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: Corticosteroid Injection
Study: NCT01022918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures)
Study: NCT01269385

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: mutation analysis
Description: Correlative studies
Study: NCT00755534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
Study: NCT02441569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard pediatric advice for childhood anxiety
Description: Providers will be free to use their existing knowledge of anxiety problems to offer routine counseling.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard pediatric advice for childhood anxiety
Description: Providers will be free to use their existing knowledge of anxiety problems to offer routine counseling.
Study: NCT03005106

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: StrataGraft Skin Tissue
Description: StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autograft
Description: The current standard of care procedure for the treatment of severe burns. The procedure involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original burn wound.
Study: NCT00755534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine (p.o) 2000 mg/m2 (1000 mg/m2 x 2) on day 1-7 every 2 weeks until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine (p.o) 2000 mg/m2 (1000 mg/m2 x 2) on day 1-7 every 2 weeks until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab(IV) 500 mg/m2 on day 1 every two weeks until progression
Study: NCT04368988

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS - Phase 1
Description: Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS (0.6 mL) on Days 0 and 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1
Description: Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS mixed with Matrix-M adjuvant (0.6 mL) on Days 0 and 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1
Description: Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS mixed with Matrix-M adjuvant (0.6 mL) on Days 0 and 21.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline solution (NSS), Placebo - Phase 1
Description: Alternating intramuscular (deltoid) injections of placebo (0.6 mL) on Days 0 and 21.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline solution (NSS), Placebo - Phase 2
Description: Intramuscular (deltoid) injections of placebo (0.5 mL).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal saline solution (NSS), Placebo - Phase 2
Description: Intramuscular (deltoid) injections of placebo (0.5 mL).
Study: NCT00755534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab(IV) 500 mg/m2 on day 1 every two weeks until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin (I.V) 85 mg/m2 on day 1 every two weeks until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin (I.V) 85 mg/m2 on day 1 every two weeks until progression
Study: NCT01958021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: Ribociclib was administered orally at a dose of 600 mg once daily (three 200 mg capsules).
Study: NCT01331408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macrolane VRF30
Description: Injection of Macrolane VRF30 in buttocks. The sum of injected volume of Macrolane VRF30 at initial treatment and touch-up must not exceed 400 ml per Subject
Study: NCT01022918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temodal/radiotherapy
Study: NCT01603628

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: Participants received intramuscular injections of botulinum toxin Type A into specified muscles of the lower limb on Day 1.
Study: NCT01958021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg tablets taken orally.
Study: NCT01603628

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: Participants received intramuscular injections of botulinum toxin Type A into specified muscles of the lower limb on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (Placebo)
Description: Participants received intramuscular injections of normal saline (placebo) into specified muscles of the lower limb on Day 1.
Study: NCT01738594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01808911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid + cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid + rituximab
Study: NCT01195636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPF-002
Description: Twice daily application of XPF-002 ointment which contains 8% of the XPF-002 active ingredient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily application of Placebo ointment
Study: NCT00315692

Intervention type: DEVICE
Intervention: Biomarker Assay (CA125 and HE4)

Intervention type: DEVICE
Intervention: Biomarker Assay (CA125 and HE4)
Study: NCT00103935

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 0.8 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 2.0 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide LAR
Description: Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 0.8 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide LAR
Description: Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 2.0 mcg.
Study: NCT04879511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Oral hypoglycemic drug metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Basal/bolus insulin
Description: Basal/bolus insulin
Study: NCT01658501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Victoza®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Victoza®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Victoza®
Study: NCT03221881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin and docetaxel
Study: NCT02792907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compressive stocking
Description: After hindfoot and middlefoot surgery the patients from the Intervention Group will be treated with compressive stockings the removal of the suture. That means from the end of week 2 until the end of week 6 after surgery.~Additionally the patients wearing behaviour is monitored by a electronic sensor, which is implanted in the patient´s stocking.
Study: NCT01658501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Victoza®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Victoza®

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet and Exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet and Exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diet and Exercise
Study: NCT01958021

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Description: Letrozole 2.5 mg tablets taken orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEE011 Placebo
Description: Matching ribociclib placebo was the control drug and was administered orally once daily.
Study: NCT01658501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Study: NCT04879511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basal/bolus insulin
Description: Basal/bolus insulin
Study: NCT03132129

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy
Description: CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy
Description: CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiography
Description: Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function.
Study: NCT01658501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylurea

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfonylurea

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and Sulfonylurea

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Sulfonylurea

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin and Sulfonylurea
Study: NCT03101865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlorenceM
Description: The automated closed loop system (FlorenceM) will consist of: Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature. An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FlorenceM
Description: The automated closed loop system (FlorenceM) will consist of: Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature. An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.
Study: NCT01777230

Intervention type: PROCEDURE
Intervention: SPECT-CT sentinel node mapping
Description: sentinel node localisation using the nuclear medicine technique SPECT-CT

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Lymphangiography sentinel node mapping
Description: Sentinel node localisation using Magnetic Resonance Lymphangiography

Intervention type: PROCEDURE
Intervention: Intra-operative sentinel node procedure
Description: Open or (robot-assisted) laparoscopic sentinel node detection and resection.
Study: NCT00822978

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACHN-490 Injection vs placebo
Description: Escalating doses beginning with test dose given once, followed by 4 mg/kg with a single dose then multiple dose. Dose escalation to continue up to 15 mg/kg as long as the treatment is deemed safe.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACHN-490 Injection vs placebo
Description: Escalating doses beginning with test dose given once, followed by 4 mg/kg with a single dose then multiple dose. Dose escalation to continue up to 15 mg/kg as long as the treatment is deemed safe.
Study: NCT01161134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam Tablets 15 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam
Description: Meloxicam Tablets 15 mg
Study: NCT02740114

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 150 mg (0.25%) injected on each side of the wound at the end of surgery before wound closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 150 mg (0.25%) injected on each side of the wound at the end of surgery before wound closure.
Study: NCT01100567

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-magnitude mechanical stimulation platform
Description: Low-magnitude mechanical stimulation platform

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low-magnitude mechanical stimulation platform
Description: Low-magnitude mechanical stimulation platform
Study: NCT03618914

Intervention type: BIOLOGICAL
Intervention: Dultavax and Vaxigrip
Description: All the women got an influenza/DTP vaccine in order to induce acute inflammation

Intervention type: BIOLOGICAL
Intervention: Dultavax and Vaxigrip
Description: All the women got an influenza/DTP vaccine in order to induce acute inflammation
Study: NCT03132129

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiography
Description: Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function.
Study: NCT01993316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitsar 201 neurofeedback
Study: NCT01155921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone Orally Disintegrating Tablets
Description: Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone Orally Disintegrating Tablets
Description: Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
Study: NCT03934970

Intervention type: DIAGNOSTIC_TEST
Intervention: Diffusion tensor imaging of peripheral nerves
Description: All subjects underwent evaluation using 1.5T DTI of median nerves and NCS. Patients underwent clinical evaluation using Neuropathy Deficit Score (NDS), Neuropathy Impairment Score in the Lower Limbs (NIS-LL) and Diabetic Neuropathy Examination (DNE) score.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diffusion tensor imaging of peripheral nerves
Description: All subjects underwent evaluation using 1.5T DTI of median nerves and NCS. Patients underwent clinical evaluation using Neuropathy Deficit Score (NDS), Neuropathy Impairment Score in the Lower Limbs (NIS-LL) and Diabetic Neuropathy Examination (DNE) score.
Study: NCT03414112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Description: oxytocin is a peptide hormone that influences social affiliation

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal oxytocin
Description: oxytocin is a peptide hormone that influences social affiliation
Study: NCT02750384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSM265 50% SDD granules
Description: Single oral dose 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSM265 50% SDD granules
Description: Single oral dose 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DSM265 25% SDD powder for suspension
Description: Single oral dose 400 mg
Study: NCT03590132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strong African American Families Program
Description: SAAF is a 7 session family skills training program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strong African American Families Program
Description: SAAF is a 7 session family skills training program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strong African American Families--Teen Program
Description: SAAF-T is a 5 session family skills training program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strong African American Families--Teen Program
Description: SAAF-T is a 5 session family skills training program
Study: NCT02744807

Intervention type: OTHER
Intervention: Chronic endometritis
Description: with or without Chronic endometritis
Study: NCT04368988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal saline solution (NSS), Placebo - Phase 2
Description: Intramuscular (deltoid) injections of placebo (0.5 mL).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal saline solution (NSS), Placebo - Phase 2
Description: Intramuscular (deltoid) injections of placebo (0.5 mL).
Study: NCT04542096

Intervention type: DEVICE
Intervention: Lung electrical impedance tomography monitoring
Description: A belt for recording changes in electrical impedance in the skin will be fastened for the purpose of this study with no other additional procedures
Study: NCT04368988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal saline solution (NSS), Placebo - Phase 2
Description: Intramuscular (deltoid) injections of placebo (0.5 mL).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal saline solution (NSS), Placebo - Phase 2
Description: Intramuscular (deltoid) injections of placebo (0.5 mL).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1
Description: Intramuscular (deltoid) injection of SARS-CoV-2 rS mixed with Matrix-M adjuvant (0.6 mL) on Day 0.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal saline solution (NSS), Placebo, Day 21 - Phase 1
Description: Intramuscular injection of placebo (0.6 mL) in alternate deltoid on Day 21.
Study: NCT04117100

Intervention type: PROCEDURE
Intervention: Polypectomy or myotomy
Description: Advanced therapeutic endoscopy can replace surgery for treatment of benign and malign GI diseases and the aim of this registry-based study to improve quality related to advanced therapeutic endoscopy because the trial will provides a quantitative method to assess advanced therapeutic practise at the CHUM and may identify practices of low quality (possible intervention) or high quality (desired). Advanced therapeutic endoscopy procedures included for this registry-based study are EMR, ESD, Assessment of polypectomy quality for colorectal adenomas/polyps, Radio Frequency Ablation (RFA) and Argon Plasma Ablation (APC), and Per Oral endoscopic Myotomy (POEM).

Intervention type: PROCEDURE
Intervention: Polypectomy or myotomy
Description: Advanced therapeutic endoscopy can replace surgery for treatment of benign and malign GI diseases and the aim of this registry-based study to improve quality related to advanced therapeutic endoscopy because the trial will provides a quantitative method to assess advanced therapeutic practise at the CHUM and may identify practices of low quality (possible intervention) or high quality (desired). Advanced therapeutic endoscopy procedures included for this registry-based study are EMR, ESD, Assessment of polypectomy quality for colorectal adenomas/polyps, Radio Frequency Ablation (RFA) and Argon Plasma Ablation (APC), and Per Oral endoscopic Myotomy (POEM).

Intervention type: PROCEDURE
Intervention: Polypectomy or myotomy
Description: Advanced therapeutic endoscopy can replace surgery for treatment of benign and malign GI diseases and the aim of this registry-based study to improve quality related to advanced therapeutic endoscopy because the trial will provides a quantitative method to assess advanced therapeutic practise at the CHUM and may identify practices of low quality (possible intervention) or high quality (desired). Advanced therapeutic endoscopy procedures included for this registry-based study are EMR, ESD, Assessment of polypectomy quality for colorectal adenomas/polyps, Radio Frequency Ablation (RFA) and Argon Plasma Ablation (APC), and Per Oral endoscopic Myotomy (POEM).